Hu­mi­ra and Ste­lara con­tin­ue to lead spe­cial­ty drug spend­ing, but new­er drugs like Keytru­da, Skyrizi are clos­ing in — re­port

Spend­ing on spe­cial­ty drugs con­tin­ues to grow, dri­ven most­ly by more peo­ple us­ing them, but al­so by in­creas­ing prices.

Spe­cial­ty drug spend­ing jumped 14.1% year …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER